论文部分内容阅读
目的评价艾迪注射液联合顺铂治疗恶性胸腔积液的临床疗效。方法将76例恶性胸腔积液患者随机分为二组,艾迪注射液联合顺铂胸腔灌注化疗组(治疗组)和单纯顺铂胸腔灌注化疗组(对照组)。治疗组和对照组每周1次胸腔内注射,2~4周为1个疗程,观察二组的胸腔积液缓解情况、生活质量变化、不良反应发生情况,毒副作用。结果治疗组治疗胸腔积液总有效率优于对照组(P<0.05),毒副作用低于对照组。治疗组消化道反应轻,骨髓抑制轻,二组差异有统计学意义(P<0.05)。结论艾迪注射液能与顺铂产生抗癌协同作用,减轻化疗毒副作用,生活质量明显改善,患者容易接受。
Objective To evaluate the clinical efficacy of Aidi injection combined with cisplatin in the treatment of malignant pleural effusion. Methods A total of 76 patients with malignant pleural effusion were randomly divided into two groups. Aidi injection combined with Cisplatin chemothorax (treatment group) and Cisplatin alone chemotherapy (control group). The treatment group and the control group were injected intrathoracially once a week for 2 to 4 weeks. The relief of pleural effusion, quality of life, adverse reactions and side effects of the two groups were observed. Results The total effective rate of treatment group was better than that of control group (P <0.05). The toxic side effects were lower than those of control group. The treatment group had mild digestive tract reaction and light bone marrow suppression. The difference between the two groups was statistically significant (P <0.05). Conclusion Aidi injection can produce anticancer synergies with cisplatin, reduce the side effects of chemotherapy, quality of life improved significantly, patients are easy to accept.